In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

All scientific resources from ESC Congress

Review slides, abstracts, videos and interviews from ESC Congress 2017 in one online FREE library

Access now
ESC TV - Guidelines

News and opinion on the latest ESC Clinical Practice Guidelines

Watch now

2017 Focused update on Dual Antiplatelet Therapy (DAPT)

ESC Clinical Practice Guidelines

Myocardial Disease
Acute Coronary Syndromes (ACS)
Cardiovascular Pharmacology and Pharmacotherapy
Guidelines version available to download
Published in 2017
Reference DAPT
Published in 2017
Reference DAPT
Published in 2017
Reference DAPT Clinical Cases
Published in 2017
Reference 2017 DAPT Congress Presentation
Published in 2017
Reference DAPT
App
Published in 2017
Reference DAPT
Published in 2017
Reference DAPT
Table of contents: Full Text (ESC Clinical Practice Guidelines)

Abbreviations and acronyms
1.  Preamble
2.  Introduction
  2.1 Short- and long-term outcomes after percutaneous coronary intervention
  2.2 Risk of stent thrombosis in relation to stent type
  2.3 Short- and long-term outcomes after coronary artery bypass surgery
  2.4 Short- and long-term outcomes after medically managed acute coronary syndrome
3. Efficacy and safety of dual antiplatelet therapy and risk stratification tools
  3.1 DAPT for the prevention of stent thrombosis
  3.2 DAPT for the prevention of spontaneous myocardial infarction
  3.3 DAPT and mortality rate
  3.4 Safety of DAPT
  3.5 Risk stratification tools for ischaemia and bleeding risks
3.6 Type of P2Y12 inhibitor and timing of initiation
3.7 Measures to minimize bleeding while on DAPT
3.8 Switching between oral P2Y12 inhibitors
4. DAPT and percutaneous coronary intervention
  4.1 DAPT after percutaneous coronary intervention for stable coronary artery disease
  4.2 DAPT after percutaneous coronary intervention for acute coronary syndrome
  4.3 Gaps in evidence
5. DAPT and cardiac surgery
  5.1 DAPT in patients treated with coronary artery bypass surgery for stable coronary artery disease
  5.2 DAPT in patients treated with coronary artery bypass surgery for acute coronary syndrome
  5.3 DAPT for prevention of graft occlusion
  5.4 Gaps in evidence
6. DAPT for patients with medically managed acute coronary syndrome
7. DAPT for patients with indication for oral anticoagulation
  7.1 Risk stratification and strategies to improve outcome after percutaneous coronary intervention
  7.2 Duration of triple therapy
  7.3 Cessation of all antiplatelet agents
  7.4 Type of anticoagulants
  7.5 Type of stent
8. Elective non-cardiac surgery in patients on DAPT
9. Gender consideration and special populations
  9.1 Gender specificities
  9.2 Diabetes mellitus
  9.3 Lower-extremities artery disease
  9.4 Complex percutaneous coronary intervention
  9.5 DAPT decision making in patients with stent thrombosis
  9.6 Patients who develop bleeding while on treatment
10. Key Messages
11. Evidenced-based “To do and not to do” messages
12. Web addenda and Clinical Cases companion document
13. Appendix
14. References